循环肿瘤DNA用于识别肌层浸润性和非器官局限性上尿路尿路上皮癌的新用途
这项前瞻性研究纳入30例接受手术切除的化疗初治高危上尿路尿路上皮癌(UTUC)患者,采用152基因组panel和低通量全基因组测序检测血浆游离DNA。检测到至少2个panel分子改变预测肌层浸润/非器官局限性UTUC的敏感性为71%、特异性为94%;联合血浆拷贝数负荷评分>6.5后敏感性升至79%、特异性94%。术前ctDNA阳性与无进展生存和癌症特异性生存强烈相关。
要点
- 30例高危UTUC患者中14例为肌层浸润/非器官局限性,21/30(70%)检出至少1个ctDNA变异。
- 至少2个panel分子改变预测MI/NOC UTUC的敏感性71%、特异性94%。
- 联合血浆拷贝数负荷评分>6.5后敏感性79%、特异性94%。
核心结论
- 术前血浆ctDNA检测对MI/NOC UTUC具有高度预测价值,并对PFS和CSS具有强烈预后价值。
- 术前ctDNA有望作为选择肾输尿管切除术前接受新辅助化疗患者的生物标志物。
研究设计与样本
- 前瞻性收集化疗初治、接受手术切除的高危UTUC患者血浆游离DNA,采用152基因组panel和低通量全基因组测序。
- 对匹配肿瘤样本进行全外显子测序以检验一致性。
- 共前瞻性纳入30例患者。
主要发现
- 30例中14例为MI/NOC UTUC。
- 21/30(70%)患者检出至少1个ctDNA变异,与匹配肿瘤样本一致性为52%。
- 至少2个panel分子改变预测MI/NOC UTUC的敏感性71%、特异性94%。
- 联合血浆拷贝数负荷评分>6.5后敏感性79%、特异性94%。
- ctDNA阳性与PFS强烈相关(1年PFS 69% vs 100%,p < 0.001),与CSS强烈相关(1年CSS 56% vs 100%,p = 0.016)。
关键数值与推荐
- 至少2个panel分子改变:预测MI/NOC UTUC敏感性71%、特异性94%。
- 至少2个panel分子改变联合血浆拷贝数负荷评分>6.5:敏感性79%、特异性94%。
- ctDNA阳性组1年PFS 69% vs ctDNA阴性组100%(p < 0.001)。
- ctDNA阳性组1年CSS 56% vs ctDNA阴性组100%(p = 0.016)。
临床怎么用
- 原文结论指出术前ctDNA有望作为选择肾输尿管切除术前接受新辅助化疗患者的生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal patient selection for neoadjuvant chemotherapy prior to surgical extirpation is limited by the inaccuracy of contemporary clinical staging methods in high-risk upper tract urothelial carcinoma (UTUC). OBJECTIVE: To investigate whether the detection of plasma circulating tumor DNA (ctDNA) can predict muscle-invasive (MI) and non-organ-confined (NOC) UTUC. DESIGN, SETTING, AND PARTICIPANTS: Plasma cell-free DNA was prospectively collected from chemotherapy-naïve, high-risk UTUC patients undergoing surgical extirpation and sequenced using a 152-gene panel and low-pass whole-genome sequencing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: To test for concordance, whole-exome sequencing was performed on matching tumor samples. The performance of ctDNA for predicting MI/NOC UTUC was summarized using the area under a receiver-operating curve, and a variant count threshold for predicting MI/NOC disease was determined by maximizing Youden's J statistic. Kaplan-Meier methods estimated survival, and Mantel-Cox log-rank testing assessed the association between preoperative ctDNA positivity and clinical outcomes. RESULTS AND LIMITATIONS: Of 30 patients enrolled prospectively, 14 were found to have MI/NOC UTUC. At least one ctDNA variant was detected from 21/30 (70%) patients, with 52% concordance with matching tumor samples. Detection of at least two panel-based molecular alterations yielded 71% sensitivity at 94% specificity to predict MI/NOC UTUC. Imposing this threshold in combination with a plasma copy number burden score of >6.5 increased sensitivity to 79% at 94% specificity. Furthermore, the presence of ctDNA was strongly prognostic for progression-free survival (PFS; 1-yr PFS 69% vs 100%, p < 0.001) and cancer-specific survival (CSS; 1-yr CSS 56% vs 100%, p = 0.016). CONCLUSIONS: The detection of plasma ctDNA prior to extirpative surgery was highly predictive of MI/NOC UTUC and strongly prognostic of PFS and CSS. Preoperative ctDNA demonstrates promise as a biomarker for selecting patients to undergo neoadjuvant chemotherapy prior to nephroureterectomy. PATIENT SUMMARY: Here, we show that DNA from upper tract urothelial tumors can be detected in the blood prior to surgical removal of the kidney or ureter. This circulating tumor DNA can be used to predict that upper tract urothelial carcinoma is invasive into the muscular lining of the urinary tract and may help identify those patients who could benefit from chemotherapy prior to surgery.
引用
- Huelster HL, Gould B, Schiftan EA, et al. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol. 2023. PMID: 37802683. doi:10.1016/j.eururo.2023.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。